Dr. Henricus de Koning on Screening in NSCLC

Video

Henricus de Koning, MD, Professor of Public Health & Screening Evaluation in the Department of Public Health of the Erasmus Medical Center in the Netherlands, discusses screening in non-small cell lung cancer (NSCLC).

There was a large randomized controlled trial in the United States that demonstrated that screening resulted in positive outcomes for NSCLC. However, after receiving screening 24% of patients in the trial were referred for further investigation. This referral rate is too high for the European healthcare system, said de Koning.

There are several European trials investigating if screening with less follow-up is effective. These trials look at the volume of the nodules in NSCLC. Patients with intermediate nodules are told to return in 3 months for an additional CT scan. This is a novel approach, that should be helpful in reducing the amount of referrals, said de Koning.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute